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Abstract
Background: Breast cancer is not a single entity but a diverse group of entities. Advances in gene expression profiling 
and immunohistochemistry as its surrogate marker have led to the unmasking of new breast cancer molecular 
subtypes, resulting in the emergence of more elaborate classification systems that are therapeutically and 
prognostically more predictive. Molecular class distribution across various ethnic groups may also reveal variations that 
can lead to different clinical outcomes in different populations.
Methods: We aimed to analyze the spectrum of molecular subtypes present in the Saudi population. ER, PR, HER2, 
EGFR and CK5/6 were used as surrogate markers for gene expression profiling to classify 231 breast cancer specimens. 
Correlation of each molecular class with Ki-67 proliferation index, p53 mutation status, histologic type and grade of the 
tumor was also carried out.
Results: Out of 231 cases 9 (3.9%) were classified as luminal A (strong ER +ve, PR +ve or -ve), 37 (16%) as luminal B 
(weak to moderate ER +ve, and/or PR +ve), 40 (17.3%) as HER2+ (strong or moderately positive HER 2 with confirmation 
by silver enhanced in-situ hybridization) and 23 (10%) as basal (CK5/6 or EGFR +ve). Co-positivity of different markers in 
varied patterns was seen in 23 (10%) of cases which were grouped into a hybrid category comprising luminal B-HER2, 
HER2-basal and luminal-basal hybrids. Ninety nine (42.8%) of the tumors were negative for all five 
immunohistochemical markers and were labelled as unclassified (penta negative). A high Ki-67 proliferation index was 
seen in basal (p = 0.007) followed by HER2+ class. Overexpression of p53 was predominantly seen in HER2 + (p = 0.001) 
followed by the basal group of tumors. A strong correlation was noted between invasive lobular carcinoma and 
hormone receptor expression with 8 out of 9 lobular carcinoma cases (88.9%) classifiable as luminal cancers. Otherwise, 
there was no association between the molecular class and the histologic type or grade of the tumor.
Conclusions: Subtyping by use of this immunohistochemical panel revealed a prevalence pattern that is unique to our 
population; luminal tumors comprised only 19.9%, and the unclassified group (penta negative) 42.8%, a distribution 
which is distinctive to our population and in contrast with all Western studies. The presence of a predominant 
unclassified group also suggests that the currently used molecular analytic spectrum may not completely encompass 
all molecular classes and there is a need to further refine and develop the existing classification systems.
Background
Breast cancer is heterogenous in its presentation, show-
ing marked diversities spanning its morphological fea-
tures, clinical outcomes, intrinsic subtypes and
prevalence patterns. In Western countries, breast cancer
is the most common female cancer and the leading cause
of cancer mortality [1]. In the Kingdom of Saudi Arabia
(KSA), although its incidence is lower than in Western
countries [2], it is ranked highest amongst all the malig-
nancies seen in Saudi females, comprising 21.8% [3].
Breast cancer in Saudi women displays features and char-
acteristics that make it distinct from what is seen in
Western nations [4]. Breast cancers in Saudi women are
generally of a high grade, are locally advanced at the time
of diagnosis, and affect predominantly females between
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46-50 years of age, which is noticeably different from the
median of 60-65 years seen in industrialized Western
nations [5], where locally advanced disease is much less
common.
The existing histological classification systems for
breast cancer are far from being accurate in predicting
the prognosis of a given patient [6]. Morphologically
identical tumors can display divergent clinical outcomes.
This can predominantly be attributed to molecular class
differences that exist amongst the histologically similar
types. A detailed knowledge about these molecular
classes and their specific identification could lead to the
development of a diagnostically more advanced and
prognostically more beneficial reporting system that
could offer much more precise prediction scores [7]. For
this reason, there is an urgent need to learn more about
the underlying biology of this disease [8].
The development of molecular analytical methods
dates back to a quarter of a century, when immunohis-
tochemistry (IHC) first allowed us to segregate these
tumors into two main classes: ER+ and ER-. A decade
later, the next step forward was the emergence of nucleic
acid in situ hybridization. This led to the identification of
two new categories, dependent on whether HER2 was
amplified or not. Many other single gene molecular
markers were assessed, but failed to prove clinically rele-
vant [9]. Further progress in this area led to development
of gene expression profiling, providing the simultaneous
quantification of multiple genes; the final results could
then be combined and used as a more reliable prognostic
and predictive score [7].
Perou et al. were the first to draft a classification system
based on gene expression analysis, and this consisted of
four major molecular classes of breast cancer: luminal-
like, basal-like, normal-like, and HER-2 positive [10].
Subsequent studies suggested the existence of more
molecular classes [11-13] and this ultimately led to addi-
tion of a fifth subtype, with the molecular analytic spec-
trum now expanding to luminal A (LUMA), luminal B
(LUMB), human epidermal growth factor receptor-2
(HER2) overexpressing, basal-like, and normal-like [12].
A further advancement in this field was the use of IHC
as a surrogate marker for gene expression profiling. Stud-
ies confirmed that it could reliably identify the major
molecular subgroups of invasive breast carcinoma [14-
16]. Recently published studies have used five IHC surro-
gate markers (ER, PR, HER2, CK5/6, and EGFR) for
molecular class distinction [17-19], with luminal tumors
being categorized by hormone receptor (HR) positivity,
HER2 expression a feature of HER 2 tumors, and CK5/6
and/or EGFR indicative of basal-like tumors. The molec-
ular dimensions were further diversified by the introduc-
tion of a hybrid category comprising the HER2 + luminal
tumors [20].
Diversities in the classification systems continue to
emerge, but current studies still lack the potential to for-
mulate a simple, practical, and easily applicable classifica-
tion system for gene expression analysis that can
completely and concisely encompass all the divergent fac-
ets of breast cancer [20]. In addition, the major studies
conducted so far are predominantly reflective of breast
cancer patterns, subtypes, and behaviour in Western
populations; there remains the need to explore these
issues in different regions.
We initially conducted a pilot study in which gene
expression profiling by real time quantitative PCR was
used to determine the "intrinsic" Saudi breast cancer sub-
types and its prevalence was compared to the more com-
monly profiled Caucasian population [19]. A comparison
between the IHC profiles of these breast cancers was cor-
related to the gene expression analysis and a discrepancy
rate of 39% was identified, most conspicuously in the
luminal type. That work suggested that breast cancer
from Saudi and Caucasian populations may have a similar
biology, but show variability in the subtype distributions.
It was concluded that analysis of a larger cohort of
patients was needed to precisely determine the molecular
taxonomy of breast cancer in the Saudi population.
The present study used a larger regional based cohort,
and the spectrum of molecular patterns seen in the Saudi
population was analyzed by combining and modifying
the current and upcoming molecular trends. The preva-
lence patterns obtained were compared and contrasted
with Western patterns and other regionally based studies.
A correlation of each subtype with Ki-67 proliferation
index, p53 mutation status, histological type and grade of
the tumor was also carried out.
Methods
Breast carcinoma cases of Saudi patients were retrieved
from the files of the Pathology Department of King Fahd
Hospital of the University (KFHU) under the approved
protocols of the research ethical committee of University
of Dammam. Patient consent was waived as many of the
cases were lost to follow up. Located in the Eastern Prov-
ince of KSA, KFHU is one of the leading teaching hospi-
tals in the Kingdom. Two hundred and thirty one cases
were randomly selected for this study based on the avail-
ability of representative blocks and sufficient tissue mate-
rial to perform the required procedures. The time frame
covered was 12 years (1997 - 2008). Out of the 231 cases,
92 (39.8%) were mastectomy specimens, 53 (23%) were
lumpectomies, and 86 (37.2%) were tru-cut biopsies. The
age of the patients ranged from 25 to 97 years with a
mean of 49.5 years (SD ± 11). The histologic type (accord-
ing to WHO classification) and grade of the tumor
(according to the modified Scarff-Bloom-Richardson
grading system) were recorded as reported in the originalAl Tamimi et al. BMC Cancer 2010, 10:223
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pathology reports. Representative cancerous tissue
obtained from paraffin blocks of mastectomy and
lumpectomy cases were incorporated into 5 tissue
microarray (TMA) reception blocks, from which sections
were cut for IHC and in situ hybridization studies. For
tru-cut biopsies, conventional paraffin blocks were uti-
lized. IHC analysis for 5 markers (ER, PR, HER2, EGFR
(HER1), and CK5/6) was used as a surrogate for gene
expression profiling to classify the carcinomas into
molecular classes. The prevalence of the different classes
was then compared to that reported in large Western and
other regional studies. Moreover, each class was corre-
lated with its Ki-67 proliferation index and p53 gene over-
expression, as revealed by IHC, and also with the histo-
logic type and grade of the tumor.
TMA construction
Two representative cancerous foci were marked on slides
with H & E-stained sections from the selected paraffin
blocks. TMAs were then created using two 0.6 mm tissue
cores from each block that were punched out and
inserted into the recipient TMA paraffin block using an
Advanced Tissue Arrayer, Model VTA-100 (Veridiam,
USA).
Immunohistochemistry
Immunohistochemical staining using the labeled strepta-
vidin-biotin (LSAB) method with 3,3'-diaminobenzidine
(DAB) as a chromagen was performed for ER, PR, HER2,
EGFR (HER1), CK5/6, Ki-67 and p53 on 4 μm thick par-
affin sections cut from TMA and conventional blocks.
The staining was performed concurrently in a Ventana
Benchmark automated immunostainer according to the
manufacturer's instructions (Ventana Medical Systems
Inc., Strasbourg). Sources and dilutions of the primary
antibodies used in the study are listed in Table 1. The
immunostained sections were examined under a light
microscope and evaluated manually by 2 pathologists
(MS and DT). In case two TMA tissue cores were scored
differently, conclusive scoring was made on a conven-
tional paraffin section from the tumor. Any interpreta-
tional discrepancies were resolved under a double-
headed microscope.
Interpretation of immunohistochemical results
ER & PR
Results were reported using a semiquantitative score (H
score) as described by Bhargava et al. [20], which assesses
the percentage of positive nuclei (cytoplasmic staining
considered negative) into categories of no staining, weak,
moderate, or strong staining. The score was given as the
sum of the percent staining multiplied by an ordinal value
corresponding to the intensity level (0 = none, 1 = weak, 2
= moderate, 3 = strong). With four intensity levels, the
resulting score ranged from 0 (no staining) to 300 (strong
diffuse staining). A score of 10 or less was considered
negative, a score of 11 - 99 weakly positive, a score of 100
- 199 moderately positive, and a score of 200 - 300
strongly positive.
HER 2/neu
Results were recorded according to the new guidelines set
by the American Society of Clinical Oncologists/College
of American Pathologists (ASCO/CAP) [21]. Positivity
for HER2 was confirmed by silver enhanced in situ
hybridization (SISH) for HER2 gene amplification as
detailed below.
EGFR
Positive staining was defined as positive membrane stain-
ing, and was scored according to the criteria originally
developed for HER 2/neu into negative, 1+, 2+ and 3+,
using 10% staining of tumor cells as the cut off point [22].
CK5/6
Positive staining was defined as cytoplasmic staining with
perinuclear enhancement. A staining intensity index was
used, defined as the product of staining intensity (0-3)
and proportion of immunoreactive cells (less than 10% =
1, 10-50% = 2, more than 50% = 3). Specimens with stain-
ing indices 1-9 were defined as positive, those with a
staining index of 0 were defined as negative [23].
Ki-67
Positive staining was defined as positive nuclear staining.
Cytoplasmic staining was considered negative. The per-
centage of positive nuclei was expressed as a "Ki-67 label-
ing index" which is the percent of cells expressing Ki-67
determined by counting 1000 cells/slide The percentage
of positive cells was scored as follows: less than 10% = low
proliferative activity, 10-40% = moderate proliferative
activity, and more than 40% = high proliferative activity
[24].
P53
Postive staining was defined as positive nuclear staining.
Cytoplasmic staining was considered negative. Tumors
were considered focally positive when unequivocal stain-
ing was present in 10-50% of tumor cells, and as diffusely
positive when more than 50% of the tumor cells were pos-
itive [25].
Silver enhanced In Situ Hybridization (SISH)
SISH for HER2 gene amplification was performed on par-
affin sections prepared from TMA and conventional
blocks in a Ventana Benchmark IHC/ISH instrument
(Ventana Medical Systems Inc., Strasbourg) according to
the manufacturer's instructions. The results were evalu-
ated by light microscopy under a 40× objective. HER2
was considered positive if there was a gene amplification
with a ratio of HER2 to the chromosome 17 centromeric
region of more than 2.2. Equivocal SISH results (ratio 1.8-
2.2) were considered negative for HER2.Al Tamimi et al. BMC Cancer 2010, 10:223
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Tumor classification
The tumors were classified into five main categories as
follows: LUMA, LUMB, HER2, basal-like, unclassified
(UC/penta-ve), and hybrid. The hybrid type was further
divided into four subtypes, Luminal B-HER2 (LBHH),
Luminal A-Basal (LABH), Luminal B-Basal (LBBH) and
HER2-Basal (HBH) Hybrids. The criteria for each class
are shown in Figure 1.
Our criteria are generally similar to previous studies
that used IHC as a surrogate for gene expression profiling
[17,18,20], though primarily corresponding to those used
by Bhargava et al. [20].
Statistical Analysis
Data were entered into the computer using SPSS for win-
dows. Comparisons between means and percentages
were done via the student's t-test, ANOVA, chi-square
and Fisher's exact test as appropriate. P < 0.05 was
regarded as significant. Frequency tables, cross-tabula-
tion, and measures of means, medians, standard devia-
tions, and graphs were performed as descriptive
statistics.
Results
Prevalence of molecular types
Of the 231 breast carcinoma cases examined, LUMA
comprised 9 (3.9%), LUMB 37 (16.0%), HER2 40 (17.3%),
basal 23 (10.0%) and unclassified (penta negative) 99
(42.8%). The cumulative hybrid category comprised 23
(10.0%). It included four subtypes, LBHH 8 (3.5%), LBBH
9 (3.9%), HBH 3 (1.3%), and LABH 3 (1.3%) (see Table 2).
Comparing the prevalence patterns in our study with
that of Western [17,18,20,26] and other regionally based
studies [27,28] revealed striking differences (see Figures 2
and 3). The main differences were in the luminal and the
unclassified groups. Luminal (HR +ve) tumors as a group
had a low prevalence in our cases (19.9%), in contrast to
its high prevalence as reported in the Western studies:
72% (Bhargava et al. [20] ), 66.9% (Carey et al. [17] ),
70.28% (Cheang et al. [26] ), 78.6% (Tamimi et al. [18] ),
and in regionally based studies from N Korea, 44.5% (Kim
et al. [27] ) and Nigeria, 80.2% (Adebamowo et al. [28] ).
In addition, LUMB (16%) was more prevalent than
LUMA (3.9%) in our study while in those other studies
LUMA was the more prevalent (ranging from 39.9 -
77.6%). Realizing that discrepancies could arise because
of the different methods used in the differentiation
between LUMA and LUMB, we grouped them together
as luminal tumors for comparison studies. The unclassi-
fied tumors represented a small group in the studies from
other regions, whereas they constituted a large propor-
tion of our cases. The prevalence of HER2 (17.31%) in our
study was also higher than that of the compared studies,
with a range of 4 - 6.6%.
A similar prevalence pattern with a still significantly
low incidence of luminal tumors (p = < 0.001 ) was
obtained when molecular classification was attempted
using other criteria previously described by several
groups [17,18,20]. Analysis with hybrid "luminal-HER2"
and "HER2-basal" cases included among luminal and
HER2 classes, respectively, yielded the following results:
Luminal 66 cases (28.5%), HER2 43 (18.6%), Basal 23
(10%) and Unclassified (penta negative) 99 (42.8%). How-
ever, the prevalence of LUMA increased from 3.9% to
25.1% (58 cases), while LUMB dropped from 16% to 3.4%
(8 cases). Yet the prevalence of LUMA was still signifi-
Table 1: Sources and dilutions of primary antibodies used in the study.
Antibody Clone Manufacturer Dilution
ER 1D5 Dako 1:200
PR PgR 636 Dako 1:50
HER2 CB11 Ventana Prediluted
CK5/6 D5/16 B4 Dako 1:50
EGFR H11 Dako 1:200
Ki67 MIB-1 Dako Prediluted
P53 D0-7 Novacastra Prediluted
ER = estrogen receptor, PR = progesterone receptor, HER2 = human epidermal growth factor receptor 2, CK5/6 = cytokeratin 5/6, EGFR = 
epidermal growth factor receptor, Ki67 = Ki67 nuclear antigen, P53 = human P53 proteinAl Tamimi et al. BMC Cancer 2010, 10:223
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cantly lower than that reported in the above mentioned
studies (p = < 0.001).
Carcinoma types & grades
In this study, invasive ductal carcinoma ( not otherwise
specified) was the predominant type, comprising 183
(79.2%) of cases, followed by invasive lobular carcinoma 9
(3.89%) of cases. In situ carcinoma comprised 15 (6.49%)
and a miscellaneous group of other rare tumors (medul-
lary carcinoma, apocrine carcinoma, mixed ductal and
lobular carcinoma, juvenile secretory carcinoma) 24
cases (10.38%). The tumors were predominantly grade 2,
104 cases (51.2%), followed by grade 3, 89 (43.8%). Grade
1 was rare, comprising only 10 (4.9%) of our cases. In
total, 203 cases were graded. The remaining were invasive
lobular carcinomas and in situ ductal carcinomas for
which the Bloom Scarf Richardson grading system is not
applicable. A strong correlation was noted between inva-
sive lobular carcinoma and hormone receptor expression
with 8 out of 9 lobular carcinoma cases (88.9%) classifi-
able as luminal cancers. Otherwise, there was no associa-
tion between the molecular class and the histologic type
or grade of the tumor (see Tables 3 &4).
Ki-67 Proliferation Index
Table 5 shows the relative prevalence of various molecu-
lar classes of tumors with a moderate to high Ki67 prolif-
eration index. The highest prevalence was noted in the
basal class (78.3% of cases), followed by hybrid (47.8%),
then HER2 (47.5%), LUMB (43.24%), UC (35.35%) and
LUMA (22.2%) classes. However, a significantly higher
value was noted only in the basal and a significantly lower
value was seen only in the LUMA (p = 0.007). In addition,
the mean Ki-67 proliferation index was significantly
higher only in the basal compared to all others, whereas
the mean values were comparable for the other types
(42.82 in the basal class vs.14.48-16 in the others, P =
0.003) (see Table 6). Comparing the Ki-67 index of the
hybrid cases with their constituents revealed that in
LBBH, the incidence of moderate to high Ki-67 indices
was lower than in both the LUMB and basal classes, but it
was closer to that of LUMB (Table 7). In LBHH, the inci-
dence was significantly higher than HER2 and LUMB (p =
0.04; see Table 8).
p53 over-expression
Focal or diffuse positivity for p53 was noted in 50 out of
the 231 (21.64%) breast cancer cases. The prevalence of
positivity for p53 is shown in Table 5. It was highest in the
HER2 (45% of cases), followed by the basal (30.4%), then
the hybrid (17.4%), UC (16.2%), and LUMB (13.5%)
classes. The level for HER2 was significantly higher than
the others (p = 0.001). p53 over-expression was not
encountered in the LUMA type. Comparing the p53 posi-
tivity of hybrid cases revealed that in LBBH the incidence
of focal to diffuse positivity was lower than in both
LUMB and basal classes but it was closer to LUMB (see
Table 7). In LBHH, the incidence was almost equal to
LUMB, and significantly lower than HER2 (p < 0.001; see
Table 8).
Discussion
In this study we have demonstrated that by using IHC as
a surrogate for gene expression profiling, there is a
unique molecular class prevalence pattern in our popula-
tion, a relative paucity of luminals and preponderance of
unclassified cases being its highlighting features. In addi-
tion, other than a strong correlation between invasive
lobular carcinoma and hormone receptor expression,
there was no association between molecular classes and
the histologic type of the cancer. This perfectly matches
with the general belief that differences in prognosis and
response to treatment within morphologically identical
tumors can largely be attributed to genetic/molecular dif-
ferences [6]. It also emphasizes a justifiable need for
Figure 1 Tumor classification (original magnification × 200). a) Lu-
minal A: ER strongly positive, PR positive or negative, HER2 negative, 
CK5/6 and EGFR negative. b) Luminal B: ER weakly to moderately posi-
tive and/or PR positive, HER2 negative, CK5/6 and EGFR negative. c) 
HER2: HER2 positive, ER and PR negative, CK5/6 and EGFR negative. d) 
Basal: CK5/6 and/or EGFR positive, ER and PR negative, HER2 negative. 
e) Unclassified (penta-ve): ER and PR negative, HER2 negative, CK5/6 
and EGFR negative. f) Hybrid: co-positivity of different markers in varied 
combination, an example of HER2-Basal hybrid (HBH) is shown.
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replacing current morphology based classification sys-
tems of breast cancer by a molecular classification that
may be more relevant prognostically [7].
Several issues in our study need to be discussed. The
unclassified category in our study comprised 42.86% of
cases, which is significantly higher than in studies by
Carey  et al. (6.25%) [17], Tamimi et al. (4.9%) [18],
Cheang et al. (8%) [26], and Bhargava et al. (4.87%) [20] (p
= < 0.001). It is also significantly higher than that
reported by Kim et al. [27] in Korean women (15.9%, p =
< 0.001). Adebamowo et al., in their study on Nigerean
women [28] did not report any cases in the unclassified
category. The presence of a dominant unclassified cate-
gory merits further investigation to gain further insight
into its nature. It highlights the inability of currently used
molecular analytic spectrum to adequately represent all
the molecular types and stresses on the immense need for
the development of new prognostic and predictive mark-
ers in breast cancer diagnosis, as has also been suggested
by Brennan et al. [29].
Unclassified cases were initially considered to be syn-
onymous with 'normal-like' breast cancers. These tumors
cluster with non-tumoral breast cancer cells and exhibit
over-expression of PIK3R1 and AKR1C1, in addition to
other genomic alterations [30]. The current concept
states that the 'normal-like' subtype is absolutely different
from the unclassified (penta negative) "ER-, PR-, HER2-,
CK5/6, and EGFR-" group, as absent or decreased expres-
sion of basal markers is not a feature compatible with the
'normal-like'  molecular class [31]. They are very good
prognostically [30] and are grouped with the luminals,
both of which exhibit low pathologic complete remission
rates of 6% [32].
According to Huo et al., the unclassified category com-
prises two contrasting branches, a bad prognostic branch,
characterized by the expression of vascular endothelial
growth factor, B-cell lymphoma extra-large protein, and
Cyclin E, and the a good prognosis branch, characterized
by expression of B-cell lymphoma protein 2 and Cyclin
D1 as its distinguishing features [33]. The unclassified
and 'normal-like'  are completely separate entities and
IHC surrogates for these categories have not yet been
developed. Associating these with a particular set of neg-
ative or absent markers may lead to misinterpretations of
their intrinsic biological characteristics [33].
In this study 35.35% of the unclassified tumors exhib-
ited a moderate to high Ki-67 proliferation index, and
16.1% demonstrated p53 mutations, suggesting the pres-
Table 2: Prevalence of molecular classes.
Number %
LUMA 9 3.9
LUMB 37 16.0
HER2 40 17.3
Basal 23 10.0
UC (penta -ve) 99 42.8
Hybrid 23 10.0
LBHH 8 3.5
LABH 3 1.3
HBH 3 1.3
LBBH 9 3.9
Total 231 100
LUMA = luminal A, LUMB = luminal B, HER2 = human epidermal growth factor receptor 2, UC = unclassified, LBHH = luminal B-HER2 hybrid, 
LABH = luminal A-basal hybrid, HBH = HER2-basal hybrid, LBBH = luminal B-basal hybrid.Al Tamimi et al. BMC Cancer 2010, 10:223
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ence of two divergent patterns of unclassified tumors in
our population. This hypothesis has not yet been vali-
dated, but further analysis of this finding is essential.
Hormone receptor positive tumors are usually diag-
nosed irrespective of stratification of receptor staining
intensity or distinction between ER and PR positivity.
Studies demonstrate that the benefit of endocrine therapy
is directly related to estrogen receptor levels [34], with
responses beginning in tumors with > 10% positive
nuclei, and increasing gradually with increased receptor
expression [35]. Strong ER+ cases benefit from endocrine
therapy alone, in contrast to those with low to moderate
ER positivity ( by Alred score) that demonstrate a better
outcome with the addition of chemotherapy [36]. There-
fore, the practice of assigning all strata of ER positivity to
one group should be revised.
The prognostic significance of PR presence, in ER +
tumors, with regards to endocrine (tamoxifen) treatment
is controversial [37]. Studies suggest that PR has no prog-
nostic predictive role in these cases [34,38]. The level of
PR positivity is an independent prognostic marker, with
Stendahl et al. demonstrating that the response to tamox-
ifen begins to be seen in tumors with more than 75% pos-
itive nuclei [35]. With these separate prognostic
implications, the concept of a conjoined ER/PR group
also merits re-evaluation.
Luminal tumors in our study comprised 19.9% of all
cases, again, a prevalence pattern that is unique to our
population. This is in stark contrast to the prevalence
pattern seen in others, specifically, the more profiled
Caucasian populations [17,18,20,26], as well as the popu-
lations from regional based studies in Korea [27] and
Nigeria [28]. LUMA represented merely 3.9% of all cases,
which is significantly less than those reported in the other
studies, which ranged from 54%-77.6% (p = < 0.001).
Analysis with hybrid "luminal-HER2" and "HER2-basal"
cases included among luminal and HER2 classes, respec-
tively [17,18,20] still yielded a significantly low prevalence
of luminal tumors including LUMA in our population.
According to studies in Western populations, Luminal-A
tumors are often the most prevalent and have a relatively
good prognosis. Adelaide et al. [39] showed luminal-A
class to be characterized by a gain of 1q, 8p12-ter, loss of
1p36-ter, and an amplification in 5q35, along with other
genetic alterations [30]. It is possible that the low repre-
sentation of luminal tumors, specifically the LUMA, seen
in our population may be reflective of a different set of
genetic alterations. This possibility requires investigation,
but such queries provide the framework for future
research.
LUMB breast cancers are characterized by expression
of HR along with HER2 associated genes (i.e., ERBB2 and
GRB7) and a cell proliferation pattern designated by
expression of MK167, CCNBI and MYBL2 [26]. They are
associated with a poorer clinical outcome than LUMA
tumors. Identification of luminal B tumors at the protein
Figure 2 Prevalence of Molecular types of breast cancer compared to 4 large Western studies.
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level is a point of controversy. Some authors have used
the co-expression of HR and HER2 to define this group,
b a s e d  o n  t h e  f a c t  t h a t  t h e  H E R 2  a s s o c i a t e d  g e n e s  ( i . e
ERBB2 and GRB7) are expressed in 30-50% of LUMB
tumors, and realizing that this will not identify all of the
tumors in this category, with a number of them ultimately
being classified as LUMA tumors [17]. Bhargava et al.
defined LUMA and LUMB as pure hormone receptor
positive, the differentiating feature between them being
the intensity of receptor positivity [20]. Cheang et al.
added that a Ki67 proliferation index of more than 13.25%
is a  ha l lm a r k of  L UM B t um ors [26]. Ki67 is a nuclear
marker of cell proliferation, and its expression correlates
proportionally to poorer clinical outcomes [40-42].
Although it is not currently included in routine clinical
decisions, recent studies [43,44], have indicated that
alterations in its levels after neo-adjuvant endocrine
treatment simultaneously alters the long-term patient
outcome. As suggested from gene expression profiling,
only 30% of LUMB tumors are HER2 positive, indicating
Figure 3 Prevalence of Molecular types of breast cancer compared to 2 large Asian and African studies.

Table 3: Correlation of molecular class with histological type of tumor.
LUMA 
No.(%)
LUMB 
No(%)
HER2 
No(%)
Basal 
No(%)
Hybrid 
No(%)
UC N0(%) Total 
No(%)
IDC 6 (3.3) 27 (14.8) 29 (15.8) 20 (10.9) 16 (8.7) 85 (46.4) 183 (79.2)
ILC 3 (33.3) 5 (55.6) 0 (0) 0 (0) 0 (0) 1 (11.1) 9 (3.89)
ISC 0 (0) 3 (20.) 7 (46.7) 0 (0) 3 (20) 2 (13.3) 15 (6.49)
Other 0 (0) 2 (8.3) 4 (16.7) 3 (12.5) 4 (16.7) 11(45.8) 24 (10.38)
IDC = Invasive ductal carcinoma, ILC = Invasive lobular carcinoma, ISC = In situ carcinoma, LUMA = luminal A, LUMB = luminal B, HER2 = 
human epidermal growth factor receptor 2, UC = unclassifiedAl Tamimi et al. BMC Cancer 2010, 10:223
http://www.biomedcentral.com/1471-2407/10/223
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that this clinical marker is not sensitive enough to iden-
tify most LUMB breast cancers [26]. These tumors are
also endocrine (tamoxifen) resistant and require estrogen
deprivation in addition to blockage of HER2 pathways
[34]. Therefore, including them as an integral component
of endocrine sensitive tumors may not be justified. Due to
these complexities, the HER2+ tumors need to be consid-
ered separately from pure luminal tumors, which should
be further categorized as luminal A and luminal B, with
those showing co-positivity of HER2 grouped into a sepa-
rate hybrid category Luminal-HER2 hybrids [20].
The prevalence of LUMB in our study (16%) was similar
to those of other studies [17,18,20]. The only study with
which this group showed a striking disparity was that of
Cheang et al. (16 vs. 32%) [26]. The reason may be that
they have used a Ki-67 proliferation index of 13.25% as a
cutoff between LUMA and LUMB, as compared with no
cutoff used by us. They demonstrated that although gene
expression profiling remains the most sensitive method,
Ki-67 proliferation added to ER, PR, and HER2 status can
be used to identify additional LUMB tumors that would
not otherwise be identified by these three markers alone
[26]. This may have led to increased expression of LUMB
in their study. Ki-67 is a well established proliferation
marker in cancer and an excellent biomarker for LUMB
tumors. Ki-67 assessment has been a matter of contro-
versy as some studies have used 10% [45,46] or 20%
[47,48] as cutoff points, while others reported use of val-
ues around the mean [49] or median [50,51]. In our study
we did not use a cutoff point but used 10% as a starting
point for moderate proliferative activity and demon-
strated that 22.2% of LUMA and 43.24% of LUMB tumors
had a moderate to high Ki-67 labeling index. As a matter
of fact, LUMA tumors showed the least prevalence of
moderate to high Ki-67 proliferation index in our study.
This is in agreement with Bhargava et al [20] who
reported the lowest average Ki-67 labeling index in their
LUMA group.
The prevalence of the HER2+ class in our study was
almost identical to that observed by Kim et al. [27] in
North Korean women (17.31% vs 17.1%). However, it was
significantly higher than the prevalence reported in each
of the other five studies that we used for the comparison
(17.31% vs. a mean of 5.33%) (p = <0.001)
Table 4: Correlation of molecular class with grade of tumors.
LUMA No 
(%)
LUMB No 
(%)
HER2 No 
(%)
Basal No 
(%)
Hybrid No 
(%)
UC No (%) Total No 
(%)
grade 1 2 (20) 3 (30) 0 (0) 2 (20) 1 (10) 2 (20) 10 (4.9)
grade 2 5 (4.3) 16(15.3) 13 (12.5) 15 (14.5) 13 (12.5) 42 (40.5) 104 (51.23)
grade 3 3 (3.4) 5 (5.6) 14 (15.7) 11 (12.3) 14 (15.7) 42 (47) 89 (43.8)
LUMA = luminal A, LUMB = luminal B, HER2 = human epidermal growth factor receptor 2, UC = unclassifiable
Table 5: Correlation of molecular class with Ki-67 and p53.
Cases with moderate to high Ki67 index Cases with focal to diffusely positive p53
No % No %
L U M A 22 2 . 20 0
LUMB 15 43.24 5 13.5
HER2 19 47.5 18 45
Basal 18 78.3 7 30.4
Hybrid 11 47.8 4 17.4
Unclassified 35 35.35 16 16.2
LUMA = luminal A, LUMB = luminal B, HER2 = human epidermal growth factor receptor 2Al Tamimi et al. BMC Cancer 2010, 10:223
http://www.biomedcentral.com/1471-2407/10/223
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[17,18,20,26,28]. This difference re-emphasizes that there
are regional variations in prevalence, a concept further
supported Al-Kuraya et al. who demonstrated that a
markedly higher frequency of HER2 and MYC amplifica-
tions are seen in Saudi as compared to Swiss breast can-
cers [2].
HER2 over-expression is prognostically unfavorable but
is associated with better responsiveness to trastuzumab
(Herceptin) therapy and anthracycline-based chemother-
apy [45]. Thus its accurate analysis and precise quantifi-
cation is essential [46] to identify patients who are eligible
for trastuzumab therapy [47].
Studies have demonstrated that the most common
mechanism (90-96%) of HER2 over-expression is by gene
amplification [45,48-50]. Both IHC and FISH have been
validated as methods for its analysis [46]. There has
recently been the introduction of bright field in situ
hybridization techniques such as chromogenic in situ
hybridization (CISH) and silver enhanced in situ hybrid-
ization (SISH). Here, a peroxidase enzyme labeled probe
with chromogenic detection is used instead of a fluores-
cent labeled probe, hence the results can be visualized by
standard bright field microscopy. Advantages over FISH
are that simultaneous histological and HER2 assessment
can be carried out; moreover the signals do not decay
over time [46]. We employed SISH for confirmation of
the HER2 positivity on all our cases.
HER2 positivity in our study was seen in two sets of
cases, exclusive HER2 positive cases and HER2 positivity
in association with luminal and basal markers as part of
the spectrum of the hybrid class. Bull et al. have demon-
strated increased frequency of p53 mutations in carcino-
mas with neu/erbB2 amplifications [51]. In our study we
also observed that 45% of HER2+ tumors demonstrated
focal or diffuse positivity, thus making HER2 the major
class exhibiting p53 mutations. This level for HER2 was
significantly higher than the other types (p = 0.001). The
combination of HER2 and p53 mutations is associated
with an increased risk of disease recurrence and overall
mortality in comparison with patients who have only one,
or neither, of the mutations [51]. p53 over-expression was
not encountered in the LUMA class which is consistent
with the fact that p53 over-expression is known to be
associated with high proliferation rates and a poor clini-
cal outcome [52].
In addition to HER2 positive LUMB cases categorized
as LBHH, we also encountered LABH, LBBH and HBH
cases (Table 2). In an attempt to define which of the
molecular classes these cases may be most similar to, we
compared the Ki-67 proliferative index and p53 expres-
s i o n  l e v e l s  i n  L U M B - b a s a l  h y b r i d  a n d  L U M B - H E R 2
hybrid cases to those of LUMB, basal, and HER2 classes.
In this context, LUMB-HER2 hybrid cases seem to repre-
sent a biological overlap between its two constituent
classes. Their p53 expression appeared at par with that of
LUMB but was significantly lower than that of HER2. On
the other hand, their Ki67 proliferation index (moderate
to high) was significantly higher than that of both the
HER2 and the LUMB molecular classes. This varied, dis-
tinctive pattern merits them an attribution of a separate
molecular class rather than a subtype of the luminal class
as conceived by several authors [17,18]. In this we agree
Table 6: Mean Ki67 index of molecular classes.
Class Mean Ki-67 index
LUMA 16
LUMB 14.48
HER2 14.62
Basal 42.82
Hybrid 16.78
UC/penta-ve 15.83
LUMA = luminal A, LUMB = luminal B, HER2 = human epidermal 
growth factor receptor 2, UC = unclassified.
Table 7: LUMB-Basal hybrid (LBBH) compared to LUMB and Basal.
Cases with moderate to high Ki-67 index Cases with focal to diffusely positive p53
No % No %
LBBH 3 30 1 10
LUMB 15 43.24 5 13.5
Basal 18 78.3 7 30.4
LBBH = luminal B-basal hybrid, LUMB = luminal BAl Tamimi et al. BMC Cancer 2010, 10:223
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with Bhargava et al. [20]. On the other hand, LUMB-basal
hybrid cases seem to be closer to the LUMB class. Conse-
quently, they may be considered as part of a "spectrum" of
the LUMB class rather than a separate subtype. This is
again in agreement with Bhargava et al. [20]. A similar
analysis was not possible for LUMA-basal and HER2-
basal hybrid cases because of their limited number (3
cases each). These preliminary observations, however,
need to be validated through clinical investigation of a
large number of patients. But it will still be important to
determine if this grouping will be valid therapeutically,
and whether the co-existence of basal markers in luminal
and HER2 categories should become the basis for a differ-
ent treatment approach.
The basal category, with a frequency of 9.95%, repre-
sented a pattern harmonious with Bhargava et al. (10.7%)
[20], Cheang et al. (9%) [26], and Tamimi et al.(10.9%)
[18]. The only study with a higher basal prevalence was
Carey et al., with 20.1% [17]. Tan et al [53] demonstrated
that increased levels of Ki 67 show a correlation with
immuno-negativity for estrogen receptors, high tumor
grade and increased mitotic activity, while in another
study Kuroda et al [54] showed high levels of Ki-67, p-53
and P-glycoprotein more in basal than in non basal types
of breast cancer. In our study too the Ki-67 index was
highest in the basal type followed by HER2, hybrids,
LUMB, UC and finally LUMA. The significantly high
Ki67 proliferation index in our basal-like class of breast
cancer is in agreement with Carey et al [17], Siziopikou &
Colbeigh [55] and Bhargava et al [20].
Triple negative breast cancer is a type of aggressive
breast cancer lacking the expression of ER, PR and HER2.
It was found to be much more frequent in BRCA 1 and
BCRA 2 positive than in BRCA-negative patients by
Atchley  et al [56]. The currently available ER-targeted
and HER-2-based therapies are not effective for treating
triple negative breast cancer. Recent studies have revealed
a number of novel molecular features of triple negative
breast cancer. Gaining better insights into these molecu-
lar pathways may lead to identification of novel biomark-
ers and targets for development of diagnostic and
therapeutic approaches for its prevention and treatment
[57]. The term "triple negative" is a term frequently used,
sometimes interchangeably with basal type, by both
researchers and clinicians. It is now accepted that not all
triple negative cancers are basal [58] and that they should
not be taken as synonymous. There is an overlap with the
basal group in 60-90% of cases and they are a component
of the unclassified penta negative type. Triple negative
tumors not exhibiting basal markers are the unclassified
or the penta negative group in our study.
Conclusions
We demonstrated that ethnic variations may exist in
molecular class prevalence pattern. A distinctive, indige-
nous distribution pattern was exhibited that was in stark
contrast with that seen in all the western studies. The
inadequacy of the currently used molecular analytic spec-
trum was also highlighted as a significant fraction of our
cases failed to express the IHC surrogate markers for the
classified molecular entities. This fact stresses on the
urgent need for further refinement and development of
the existing classification systems. Expression of novel
combinations of molecular classes forming various sub-
classes were demonstrated in the newly emerging hybrid
category of tumors. This could, in the future alter and
modify the course of therapeutic strategies, that are cur-
rently more class specific.
Our knowledge about breast cancer molecular classes
has increased tremendously, but beyond a certain limit,
there are queries and dilemmas that still remain unan-
swered, and which remain important for future studies.
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